市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Cue Biopharma, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.21 |
|
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.35% |
| 机构持股比例 | 19.45% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Tetragon Partners Gp Ltd | 30 Jun 2026 | 93,819 |
| Stempoint Capital Lp | 30 Jun 2026 | 66,995 |
| Lion Point Capital, Lp | 30 Jun 2026 | 52,928 |
| Squadron Capital Management Llc | 30 Jun 2026 | 50,000 |
| Boothbay Fund Management, Llc | 30 Jun 2026 | 31,459 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合